Profile data is unavailable for this security.
About the company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
- Revenue in USD (TTM)0.00
- Net income in USD-88.07m
- Incorporated2020
- Employees66.00
- LocationTerns Pharmaceuticals Inc1065 East Hillsdale Blvd.Suite 100, Suite 100FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 525-5535
- Fax+1 (650) 275-4395
- Websitehttps://ternspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACELYRIN Inc | 0.00 | -264.41m | 469.10m | 130.00 | -- | 0.8949 | -- | -- | -2.68 | -2.68 | 0.00 | 5.29 | 0.00 | -- | -- | 0.00 | -37.27 | -- | -41.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| OmniAB Inc | 20.41m | -63.02m | 471.27m | 106.00 | -- | 1.71 | -- | 23.09 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Regenxbio Inc | 84.33m | -238.81m | 475.14m | 344.00 | -- | 1.57 | -- | 5.63 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 479.58m | 38.00 | -- | 569.13 | -- | 10.00 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 482.30m | 49.00 | -- | 2.50 | -- | -- | -- | -- | -- | 3.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0039 | -- | -- | -- | -58.47 | -- | -- | -- |
| Celcuity Inc | 0.00 | -93.97m | 489.74m | 55.00 | -- | 3.45 | -- | -- | -2.61 | -2.61 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -45.24 | -37.32 | -49.93 | -39.16 | -- | -- | -- | -- | -- | -- | 0.393 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Korro Bio Inc | 0.00 | -101.60m | 490.05m | 95.00 | -- | 2.70 | -- | -- | -17.04 | -17.04 | 0.00 | 19.28 | 0.00 | -- | -- | 0.00 | -70.10 | -31.55 | -76.20 | -36.48 | -- | -- | -- | -365.87 | -- | -104.93 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -88.07m | 491.80m | 66.00 | -- | 1.35 | -- | -- | -1.18 | -1.18 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -27.10 | -41.34 | -28.12 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| ProKidney Corp | 0.00 | -45.61m | 492.91m | 163.00 | -- | -- | -- | -- | -0.5541 | -0.5541 | 0.00 | -3.36 | 0.00 | -- | -- | 0.00 | -29.48 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 498.18m | 150.00 | -- | 2.51 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Zenas Biopharma Inc | 0.00 | -128.97m | 501.49m | 115.00 | -- | 1.31 | -- | -- | -3.19 | -3.19 | 0.00 | 8.60 | 0.00 | -- | -- | 0.00 | -52.94 | -- | -60.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -122.68m | 503.08m | 87.00 | -- | 2.57 | -- | -- | -2.19 | -2.19 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -46.92 | -30.06 | -51.51 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 506.21m | 52.00 | -- | 6.67 | -- | 51.05 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Alumis Inc | 0.00 | -238.77m | 514.66m | 145.00 | -- | 1.47 | -- | -- | -4.52 | -4.52 | 0.00 | 6.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Terns Pharmaceuticals Inc's reporting currency: US Dollar USD
40.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2024 | 6.22m | 7.37% |
| Deep Track Capital LPas of 30 Sep 2024 | 5.58m | 6.60% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.15m | 4.91% |
| Citadel Advisors LLCas of 30 Sep 2024 | 3.36m | 3.99% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.30m | 3.91% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2024 | 3.29m | 3.90% |
| Point72 Asset Management LPas of 30 Sep 2024 | 2.71m | 3.21% |
| Avidity Partners Management LPas of 30 Sep 2024 | 2.13m | 2.53% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 2.09m | 2.48% |
| ExodusPoint Capital Management LPas of 30 Sep 2024 | 1.65m | 1.95% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
